Microbiota-gut-brain Axis and Cns Disorders: Recent Progress and Perspectives. This item is unavailable.Microbiota-gut-brain Axis and Cns Disorders: Recent Progress and Perspectives

• Discusses the development of both health and disease in interdisciplinary research involving gut microbiology
• Provides an understanding the role of Microbiome-Gut-Brain axis in neurodegenerative and neurodevelopmental diseases, including central nervous system (CNS) malignancies
• Delivers a compilation of current clinical studies to further investigate the role of diet in varying neurological disorders

Neeraj Mishra is Professor and Head of the Department of Pharmaceutics at the Amity Institute of Pharmacy, Amity University Madhya Pradesh, Gwalior, India. His academic work focuses on novel drug delivery systems, including localized, targeted, and controlled delivery approaches using nanocarrier and microparticle-based technologies. His research interests encompass therapies for cancer and neurodegenerative disorders, and he has extensive experience in teaching, research supervision, and scholarly publishing. He has also contributed to innovation in pharmaceutical sciences through intellectual property development and collaborative academic activities. Through his research and educational initiatives, he supports the advancement of drug delivery strategies and pharmaceutical research.

Anoop Kumar is Assistant Professor in the Department of Pharmacology at the Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), Delhi Pharmaceutical Sciences and Research University (DPSRU), Government of NCT of Delhi, India. He has held academic and research positions in pharmaceutical education, translational research, and the pharmaceutical industry. His professional activities include teaching, research, editorial service, ethics committee responsibilities, and engagement with professional organizations. His research interests include drug repurposing, meta-analysis of clinical trials, network pharmacology, pharmacoeconomics, pharmacovigilance, and experimental pharmacology. He has contributed to scientific publishing and research initiatives that support evidence-based approaches to drug discovery, development, and healthcare decision-making.